CA2824885A1 - Binding proteins to inhibitors of coagulation factors - Google Patents

Binding proteins to inhibitors of coagulation factors Download PDF

Info

Publication number
CA2824885A1
CA2824885A1 CA2824885A CA2824885A CA2824885A1 CA 2824885 A1 CA2824885 A1 CA 2824885A1 CA 2824885 A CA2824885 A CA 2824885A CA 2824885 A CA2824885 A CA 2824885A CA 2824885 A1 CA2824885 A1 CA 2824885A1
Authority
CA
Canada
Prior art keywords
antibody
seq
antigen
cdr
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2824885A
Other languages
English (en)
French (fr)
Inventor
Frank Dittmer
Anja Buchmuller
Christoph Gerdes
Adrian Tersteegen
Mark Jean Gnoth
Lars Linden
Axel Harrenga
Joanna Grudzinska-Goebel
Mario Jeske
Martina Schafer
Jorg Birkenfeld
Holger Paulsen
Ricarda Finnern
Anke Mayer-Bartschmid
Andrea Eicker
Simone Greven
Susanne Steinig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of CA2824885A1 publication Critical patent/CA2824885A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2824885A 2011-01-19 2012-01-17 Binding proteins to inhibitors of coagulation factors Abandoned CA2824885A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11151410.5 2011-01-19
EP11151410 2011-01-19
PCT/EP2012/050595 WO2012098089A1 (en) 2011-01-19 2012-01-17 Binding proteins to inhibitors of coagulation factors

Publications (1)

Publication Number Publication Date
CA2824885A1 true CA2824885A1 (en) 2012-07-26

Family

ID=45491612

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2824885A Abandoned CA2824885A1 (en) 2011-01-19 2012-01-17 Binding proteins to inhibitors of coagulation factors

Country Status (7)

Country Link
US (1) US20140050743A1 (https=)
EP (1) EP2665751A1 (https=)
JP (1) JP2014506448A (https=)
CN (1) CN103619883A (https=)
AR (1) AR084886A1 (https=)
CA (1) CA2824885A1 (https=)
WO (1) WO2012098089A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017237543B2 (en) * 2016-03-23 2020-02-06 Institut Pasteur Korea Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
EP3577140A1 (en) 2017-02-01 2019-12-11 Novo Nordisk A/S Procoagulant antibodies
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US6669937B2 (en) * 2000-04-20 2003-12-30 The Board Of Trustees Of The University Of Arkansas Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
RU2319699C2 (ru) 2001-06-20 2008-03-20 Дайити Санкио Компани, Лимитед Производные диаминов
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
CN104744461A (zh) 2001-09-21 2015-07-01 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
EP2915564B1 (en) 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
MX2011004907A (es) * 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante

Also Published As

Publication number Publication date
JP2014506448A (ja) 2014-03-17
AR084886A1 (es) 2013-07-10
US20140050743A1 (en) 2014-02-20
CN103619883A (zh) 2014-03-05
EP2665751A1 (en) 2013-11-27
WO2012098089A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
US20100291106A1 (en) Compositions and methods for antibodies targeting complement protein c3b
CN107428838B (zh) 结合tfpi的新型抗体以及包含所述抗体的组合物
JP2014511378A (ja) Ｐｃｓｋ９アンタゴニスト
JP2014509856A (ja) ヒト組織因子抗体及びその使用
AU2014281294A1 (en) Lectin-like oxidized LDL receptor1 antibodies and methods of use
CA2824885A1 (en) Binding proteins to inhibitors of coagulation factors
US20210395390A1 (en) Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
JP2019509714A (ja) Ｐｃｓｋ９抗体、その抗原結合フラグメント及び医薬用途
US12215168B2 (en) Anti-A2AP antibodies and uses thereof
CN117545782A (zh) 针对XIa因子抑制剂的抗体和抗原结合肽及其用途
US12065505B2 (en) Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereof
RU2844816C1 (ru) Новые антитела против a2ap и их применение
TW201245226A (en) Binding proteins to inhibitors of coagulation factors
HK1190726A (en) Binding proteins to inhibitors of coagulation factors
HK40010475B (zh) Gremlin-1晶体结构和抑制性抗体

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20180117